טוען...
Pretreatment of daily teriparatide enhances the increase of bone mineral density in cortical bones by denosumab therapy
BACKGROUND: While it is well known that teriparatide (TPTD) increases bone mineral density (BMD) in osteoporotic patients, it is unknown whether TPTD pretreatment affects BMD after denosumab (DMAb) therapy. METHODS: Fifty-seven patients in TPTD-pretreated group and 35 patients in DMAb-alone group ha...
שמור ב:
| הוצא לאור ב: | Ther Clin Risk Manag |
|---|---|
| Main Authors: | , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Dove Medical Press
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5892610/ https://ncbi.nlm.nih.gov/pubmed/29662314 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S154686 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|